Anna Zaghini

Prof. Anna Zaghini

Veterinary Medical Sciences, Alma Mater Studiorum Università di Bologna, Bologna, Emilia-Romagna, Italy
orcid
Full Professor Vet Pharm Tox; Degree Pharmac Chemistry and T...

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ACAlice Caneschi
Alice Caneschi
ABAnisa Bardhi
Anisa Bardhi
ABAndrea Barbarossa
Andrea Barbarossa
AZAnna Zaghini
Anna Zaghini
As warned by Sir Alexander Fleming in his Nobel Prize address: “the use of antimicrobials can, and will, lead to resistance”. Antimicrobial resistance (AMR) has recently increased due to the overuse and misuse of antibiotics, and their use in animals (food-producing and companion) has also resulted in the selection and transmission of resistant bacteria. The epidemiology of resistance is complex, and factors other than the overall quantity of antibiotics consumed may influence it. Nowadays, AMR has a serious impact on society, both economically and in terms of healthcare. This narrative review aimed to provide a scenario of the state of the AMR phenomenon in veterinary medicine related to the use of antibiotics in different animal species; the impact that it can have on animals, as well as humans and the environment, was considered. Providing some particular instances, the authors tried to explain the vastness of the phenomenon of AMR in veterinary medicine due to many and diverse aspects that cannot always be controlled. The veterinarian is the main reference point here and has a high responsibility towards the human–animal–environment triad. Sharing such a burden with human medicine and cooperating together for the same purpose (fighting and containing AMR) represents an effective example of the application of the One Health approach.

16 September 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AVAndrea Vannini
Andrea Vannini
VLValerio Leoni
Valerio Leoni
CBCatia Barboni
Catia Barboni
MSMara Sanapo
Mara Sanapo
AZAnna Zaghini
Anna Zaghini
TGTatiana Gianni
Tatiana Gianni
Significance: The PD-1/PD-L1 axis is a master player in the tumor immune evasion strategy. Checkpoint inhibitors, including anti–PD-1/PD-L1, are revolutionizing cancer immunotherapy. There is intense interest in dissecting their regulation and improving their application, mainly by combination therapies. The significance of the current findings is 2-fold. Our results suggest αvβ3-integrin as a critical regulator of PD-L1 expression and a key component of the tumor immune evasion machinery. Indeed, αvβ3-integrin depletion impairs tumor growth and elicits immunotherapeutic protection. Second, αvβ3-integrin blockade primes tumors for anti–PD-1 therapy and induces durable anticancer immune protection when combined with anti–PD-1 therapy. αvβ3-integrin is a readily druggable target that adds to the list of molecules suitable for combinatorial cancer immunotherapy.

1 September 2013 in Experimental and Toxicologic Pathology
Verified
Journal Article
Closed access
PAPietro Apostoli
Pietro Apostoli
SCSimona Catalani
Simona Catalani
AZAnna Zaghini
Anna Zaghini
AMAndrea Mariotti
Andrea Mariotti
Pietro Luigi PolianiPietro Luigi Poliani
Pietro Luigi Poliani
RCRaffaele De Caro
Raffaele De Caro

3 January 2021 in Aging Cell
Verified
Journal Article
Open access
PDF file
SSStefano Squarzoni
Stefano Squarzoni
ESElisa Schena
Elisa Schena
PSPatrizia Sabatelli
Patrizia Sabatelli
EMElisabetta Mattioli
Elisabetta Mattioli
CCCristina Capanni
Cristina Capanni
Giovanna LattanziGiovanna Lattanzi
Giovanna Lattanzi
Hutchinson–Gilford progeria syndrome (HGPS) causes premature aging in children, with adipose tissue, skin and bone deterioration, and cardiovascular impairment. In HGPS cells and mouse models, high levels of interleukin‐6, an inflammatory cytokine linked to aging processes, have been detected. Here, we show that inhibition of interleukin‐6 activity by tocilizumab, a neutralizing antibody raised against interleukin‐6 receptors, counteracts progeroid features in both HGPS fibroblasts and LmnaG609G/G609G progeroid mice. Tocilizumab treatment limits the accumulation of progerin, the toxic protein produced in HGPS cells, rescues nuclear envelope and chromatin abnormalities, and attenuates the hyperactivated DNA damage response. In vivo administration of tocilizumab reduces aortic lesions and adipose tissue dystrophy, delays the onset of lipodystrophy and kyphosis, avoids motor impairment, and preserves a good quality of life in progeroid mice. This work identifies tocilizumab as a valuable tool in HGPS therapy and, speculatively, in the treatment of a variety of aging‐related disorders.

6 August 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
VLValerio Leoni
Valerio Leoni
AVAndrea Vannini
Andrea Vannini
VGValentina Gatta
Valentina Gatta
JRJulie Rambaldi
Julie Rambaldi
MSMara Sanapo
Mara Sanapo
GCGabriella Campadelli-Fiume
Gabriella Campadelli-Fiume
Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice. Most of them gain cancer-specificity from deletions/mutations in genes that counteract the host response, and grow selectively in cancer cells defective in anti-viral response. Because of the deletions/mutations, they are frequently attenuated or over-attenuated. We developed next-generation oHSVs, which carry no deletion/mutation, gain cancer-specificity from specific retargeting to tumor cell receptors—e.g. HER2 (human epidermal growth factor receptor 2)—hence are fully-virulent in the targeted cancer cells. The type of immunotherapy they elicit was not predictable, since non-attenuated HSVs induce and then dampen the innate response, whereas deleted/attenuated viruses fail to contrast it, and since the retargeted oHSVs replicate efficiently in tumor cells, but spare other cells in the tumor. We report on the first efficacy study of HER2-retargeted, fully-virulent oHSVs in immunocompetent mice. Their safety profile was very high. Both the unarmed R-LM113 and the IL-12-armed R-115 inhibited the growth of the primary HER2-Lewis lung carcinoma-1 (HER2-LLC1) tumor, R-115 being constantly more efficacious. All the mice that did not die because of the primary treated tumors, were protected from the growth of contralateral untreated tumors. The long-term survivors were protected from a second contralateral tumor, providing additional evidence for an abscopal immunotherapeutic effect. Analysis of the local response highlighted that particularly R-115 unleashed the immunosuppressive tumor microenvironment, i.e. induced immunomodulatory cytokines, including IFNγ, T-bet which promoted Th1 polarization. Some of the tumor infiltrating cells, e.g. CD4+, CD335+ cells were increased in the tumors of all responders mice, irrespective of which virus was employed, whereas CD8+, Foxp3+, CD141+ were increased and CD11b+ cells were decreased preferentially in R-115-treated mice. The durable response included a breakage of tolerance towards both HER2 and the wt tumor cells, and underscored a systemic immunotherapeutic vaccine response. There is increasing interest in oncolytic viruses (OVs), following the approval of OncovexGM-CSF, and the success of a number of them in clinical trials. Most OVs, particularly the oHSVs, are attenuated to varying degree. In contrast, the tropism-retargeted oHSVs are fully-virulent, highly effective oncolytic agents, and appear to be highly safe in mice. Up to now, it was unknown how efficacious the retargeted oHSVs are as immunotherapeutic agents. Here, the demonstration that they elicit local immune response and systemic therapy vaccine effects opens the possibility that the fully-virulent retargeted oHSVs may be highly efficacious oncolytic-immunotherapeutic agents.

29 October 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
Marianna PaulettoMarianna Pauletto
Marianna Pauletto
MGMery Giantin
Mery Giantin
RTRoberta Tolosi
Roberta Tolosi
IBIrene Bassan
Irene Bassan
ABAndrea Barbarossa
Andrea Barbarossa
MDMauro Dacasto
Mauro Dacasto
Aflatoxin B1 (AFB1) toxicity in livestock and human beings is a major economic and health concern. Natural polyphenolic substances with antioxidant properties have proven to be effective in ameliorating AFB1-induced toxicity. Here we assessed the potential anti-AFB1 activity of curcumin (pure curcumin, C, and curcumin from Curcuma longa, CL) in a bovine fetal hepatocyte-derived cell line (BFH12). First, we measured viability of cells exposed to AFB1 in presence or absence of curcumin treatment. Then, we explored all the transcriptional changes occurring in AFB1-exposed cells cotreated with curcumin. Results demonstrated that curcumin is effective in reducing AFB1-induced toxicity, decreasing cells mortality by approximately 30%. C and CL induced similar transcriptional changes in BFH12 exposed to AFB1, yet C treatment resulted in a larger number of significant genes compared to CL. The mitigating effects of curcuminoids towards AFB1 toxicity were mainly related to molecular pathways associated with antioxidant and anti-inflammatory response, cancer, and drug metabolism. Investigating mRNA changes induced by curcumin in cattle BFH12 cells exposed to AFB1 will help us to better characterize possible tools to reduce its consequences in this susceptible and economically important food-producing species.